Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Open Access
- 10 April 2020
- Vol. 12 (4), 942
- https://doi.org/10.3390/cancers12040942
Abstract
To date, no head-to-head trials have compared the efficacy of brigatinib and alectinib against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor-naïve, advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. We conducted an indirect treatment comparison (ITC) between brigatinib and alectinib, with crizotinib as a common comparator, using a Bayesian model with non-informative prior distribution and assessed the between-study heterogeneity of the studies. The primary efficacy endpoint was progression-free survival (PFS), and efficacy was ranked using the surface under the cumulative ranking (SUCRA) curve values. ITC analysis showed that there were no significant differences in PFS between the brigatinib and alectinib arms. However, the SUCRA values revealed that alectinib ranked the highest by efficacy in the overall patient population, whereas brigatinib ranked the highest by efficacy in the CNS metastasis sub-group. Although there were no significant differences in the incidence of G3–5 adverse events between the brigatinib and alectinib arms in the overall patient population, the data were deemed insufficient for the CNS metastasis sub-group analysis. This study provides critical information to clinicians regarding the efficacy of brigatinib for ALK-p, ALK-inhibitor-naïve, advanced NSCLC patients, with and without CNS metastasis. Larger randomized, controlled trials are warranted to confirm our results.This publication has 54 references indexed in Scilit:
- Evidence Synthesis for Decision Making 3Medical Decision Making, 2013
- Evidence Synthesis for Decision Making 4Medical Decision Making, 2013
- Evidence Synthesis for Decision Making 2Medical Decision Making, 2012
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJournal of Clinical Epidemiology, 2011
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLoS Medicine, 2009
- Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment ComparisonsValue in Health, 2008
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Network meta‐analysis for indirect treatment comparisonsStatistics in Medicine, 2002
- Markov Chain Monte Carlo Estimation of a Multiparameter Decision Model: Consistency of Evidence and the Accurate Assessment of UncertaintyMedical Decision Making, 2002
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002